Welcome to my Blog.... Mesothelioma

Abdominal Mesothelioma, Mesothelioma, Mesothelioma diagnosis, Mesothelioma Lawyer

==============================================================================

Saturday, August 2, 2008

Fwd: Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.
To: mesothelioma77@gmail.com


[1]Prostate. 2008 Jul 30;
Mubiru JN, Hubbard GB, Dick EJ, Furman J, Troyer DA, Rogers J

BACKGROUND: Because prostate specific antigen (PSA) is released at increased levels into the blood early in the development of prostate cancer, benign prostatic hyperplasia (BPH) and prostatitis, it is widely used as a marker for these diseases. However, PSA has clinical limitations as a screen for prostatic diseases due to its low sensitivity and specificity. There is a strong need to better understand the biology of PSA and factors affecting its serum levels. METHODS: We evaluated cynomolgus macaques, rhesus macaques, baboons, and marmosets for their suitability as models for the study of PSA biology and prostatic diseases. RESULTS: Prostates of several nonhuman primates are anatomically similar to the human counterpart. Anti-human PSA antibody detected PSA antigens in all the Old World monkeys (cynomolgus macaques, rhesus macaques, and baboons) but not in marmosets. Of the Old World monkeys, cynomolgus macaques have the highest serum PSA levels; baboons have the lowest. Serum PSA levels from macaques includes a number of outlier samples with unusually high values. We also report two cases of abnormal pathologies in macaques accompanied by high serum PSA levels. One case consisted of prostatic hyperplasia involving both glandular and basal cells in a cynomolgus macaque and another of glandular hyperplasia and atrophy in a rhesus macaque. The finding that pathological changes in the prostate of macaques may lead to increases in serum PSA is worthy of further exploration. CONCLUSION: Cynomolgus macaques and rhesus macaques are promising animal models for PSA biology studies. Prostate (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18668524
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Implementing a system of quality-of-life diagnosis and therapy for breast cancer patients: results of an exploratory trial as a prerequisite for a subsequent RCT.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Implementing a system of quality-of-life diagnosis and therapy for breast cancer patients: results of an exploratory trial as a prerequisite for a subsequent RCT.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Aug 5; 99(3): 415-22
Klinkhammer-Schalke M, Koller M, Ehret C, Steinger B, Ernst B, Wyatt JC, Hofstädter F, Lorenz W

A system for quality-of-life diagnosis and therapy (QoL system) was implemented for breast cancer patients. The system fulfilled the criteria for complex interventions (Medical Research Council). Following theory and modeling, this study contains the exploratory trial as a next step before the randomised clinical trial (RCT) answering three questions: (1) Are there differences between implementation sample and general population? (2) Which amount and type of disagreement exist between patient and coordinating practitioners (CPs) in assessed global QoL? (3) Are there empirical reasons for a cutoff of 50 points discriminating between healthy and diseased QoL? Implementation was successful: 74% of CPs worked along the care pathway. However, CPs showed preferences for selecting patients with lower age and UICC prognostic staging. Patients and CPs disagreed considerably in values of global QoL, despite education in QoL assessment by outreach visits, opinion leaders and CME: Zero values of QoL were only expressed by patients. Finally, the cutoff of 50 points was supported by the relationship between QoL in single items and global QoL: no patients with values above 50 dropped global QoL below 50, but values below 50 and especially at 0 points in single items, induced a dramatic fall of global QoL down to below 50. The exploratory trial was important for defining the complex intervention in the definitive RCT: control for age and prognostic stage grading, support for a QoL unit combining patient's and CP's assessment of QoL and support for the 50-point cutoff criterion between healthy and diseased QoL.British Journal of Cancer (2008) 99, 415-422. doi:10.1038/sj.bjc.6604505 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18665187
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Aug 5; 99(3): 513-9
Li L, Mu K, Zhou G, Lan L, Auer G, Zetterberg A

The role of genomic instability and proliferative activity for development of distant metastases in breast cancer was analysed, and the relative contribution of these two risk factors was quantified. A detailed quantitative comparison was performed between Ki67 and cyclin A as proliferative markers. The frequency of Ki67 and cyclin A-positive cells was scored in the same microscopic areas in 428 breast tumours. The frequency of Ki67-positive cells was found to be highly correlated with the frequency of cyclin A-positive cells, and both proliferation markers were equally good to predict risk of distant metastases. The relative contribution of degree of aneuploidy and proliferative activity as risk markers for developing distant metastases was studied independently. Although increased proliferative activity in general was associated with an increased risk of developing distant metastases, ploidy level was found to be an independent and even stronger marker when considering the group of small (T1) node negative tumours. By combining proliferative activity and ploidy level, a large group of low risk breast tumours (39%) could be identified in which only a few percentage of the tumours (5%) developed distant metastases during the 9-year follow-up time period.British Journal of Cancer (2008) 99, 513-519. doi:10.1038/sj.bjc.6604479 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18665192
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Promises and caveats of in silico biomarker discovery.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Promises and caveats of in silico biomarker discovery.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Aug 5; 99(3): 385-6
Pusztai L, Leyland-Jones B





___
Source: http://www.hubmed.org/display.cgi?uids=18665186
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 [6] <http://www.blueskyfactory.com/>

Fwd: The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jul 29;
Robinson D, Holmberg L, Møller H

Approximately 1 in every 600 women attending breast-screening programmes in the United Kingdom is diagnosed with breast carcinoma in situ (BCIS). However, there is little information on the occurrence of subsequent cancers (other than second breast cancers) in these women. We investigated the occurrence of invasive cancers in 12 836 women diagnosed with BCIS in southeast England between 1971 and 2003, using data from the Thames Cancer Registry. A greater than expected number of subsequent cancers was found for two sites: breast (standardised incidence ratio (SIR) 1.96; 95% confidence interval (CI) 1.79-2.14) and corpus uteri (SIR 1.42; 95% CI 1.11-1.78). For subsequent ipsilateral breast cancer in those treated with breast conservation, the excess was independent of the time since diagnosis of BCIS, whereas for subsequent contralateral breast cancer, there was a steady decline in excess over time. For subsequent uterine cancer, the excess became statistically significant only at >5 years after BCIS diagnosis, consistent with a treatment effect. This was further supported by Cox regression anaysis: the risk of subsequent uterine cancer was significantly increased in women receiving hormonal therapy compared with those not receiving it, with a hazard ratio of 2.97 (95% CI 1.84-4.80).British Journal of Cancer advance online publication, 29 July 2008; doi:10.1038/sj.bjc.6604524 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18665169
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Friday, August 1, 2008

Fwd: Disruption of arginase II alters prostate tumor formation in TRAMP mice.



---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 30, 2008 at 9:30 PM
Subject: Disruption of arginase II alters prostate tumor formation in TRAMP mice.
To: mesothelioma77@gmail.com


[1]Prostate. 2008 Jul 28;
Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, Grody WW

BACKGROUND: Arginase II (AII) is involved in the polyamine synthetic pathway, and elevated levels of expression have been found in a high proportion of prostate cancer samples and patients. However, the biological function of arginase II in prostate cancer still remains to be elucidated. In this study, we utilized the TRAMP mouse prostate cancer model to better understand the contribution of AII on tumor development. METHODS: AII expression was determined in prostates from TRAMP mice at 23 weeks of age by real-time RT-PCR and Western blot analysis. Additionally, AII expression was disrupted in the TRAMP model by crossbreeding arginase II knockout (AII KO) mice with TRAMP mice in order to generate the TRAMP/AII KO line. In each group, genito-urinary (GU) tract weights were determined and a pathological evaluation of the tumors was completed. RESULTS: AII expression was only detectable in those mice without the presence of macroscopic tumors; it was also absent in the TRAMP-C2 cell line, which is characteristic of an advanced prostate tumor. Assessment of the GU weights revealed larger average GU weights in the TRAMP/AII KO mice compared to TRAMP mice. Additionally, a greater percentage of more advanced pathology was found in the TRAMP/AII KO group compared to the TRAMP cohort. CONCLUSIONS: Based on these results, AII deficiency in the TRAMP model seems to accelerate prostate tumor progression, leading to an overall more advanced cancer stage in these mice. These findings support the possibility that prostatic arginase II could be a potentially useful marker of disease progression. Prostate (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18663728
--
 
~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 http://www.aseanface.com/display_blog.php
 
 
Links for Aseanface Humor
 
 

Fwd: Disparities in Urban and Rural Mastectomy Populations : The Effects of Patient- and County-Level Factors on Likelihood of Receipt of Mastectomy.



---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Wed, Jul 30, 2008 at 9:30 PM
Subject: Disparities in Urban and Rural Mastectomy Populations : The Effects of Patient- and County-Level Factors on Likelihood of Receipt of Mastectomy.
To: mesothelioma77@gmail.com


[1]Ann Surg Oncol. 2008 Jul 29;
Jacobs LK, Kelley KA, Rosson GD, Detrani ME, Chang DC

BACKGROUND: Using the 2006 Surveillance, Epidemiology, and End Results (SEER) database and the 2004 Area Resource File (ARF), the likelihood of mastectomy for stages I-III breast cancer patients in urban versus rural populations are examined. County and patient level data are evaluated for impact on receipt of mastectomy. Patient variables included age, stage, race, and marital status, and community variables are income, employment, and radiation facility staff density. The likelihood of mastectomy in urban and rural patients, and the impact of the different variables on that procedure, is reported. METHODS: This retrospective analysis of a combined dataset from the 2006 SEER database and the 2004 ARF linked using the federal information processing standard (FIPS) state county variable evaluates patient and county variables with multivariate regression. RESULTS: From 1992 to 2003, 137,303 patients were identified in the SEER database. The rural population (county population of

___
Source: http://www.hubmed.org/display.cgi?uids=18663535
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc